导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.70% | 2872/4773 |
| 近一周 | -2.08% | 3354/5465 |
| 近一月 | -5.15% | 3639/5421 |
| 近一季 | -7.56% | 2874/5231 |
| 近半年 | -3.93% | 2652/4920 |
| 近一年 | 1.84% | 2408/4394 |
| 近两年 | 39.63% | 1921/2954 |
| 近三年 | 20.34% | 1472/2253 |
| 成立以来 | 51.46% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.86% 2933/4961 |
12.81% 2117/5312 |
- - |
- - |
| 2025 | 21.96% 2007/4813 |
0.75% 1777/3635 |
1.03% 2492/4076 |
19.26% 2168/4524 |
0.47% 1980/4813 |
| 2024 | 8.60% 1534/3463 |
2.66% 734/2808 |
-1.20% 974/3014 |
13.42% 2168/3129 |
-5.61% 2574/3463 |
| 2023 | -11.02% 1362/2656 |
4.64% 895/2280 |
-4.96% 1329/2385 |
-3.85% 1004/2515 |
-6.95% 1990/2655 |
| 2022 | -20.03% 925/2207 |
-12.96% 676/1919 |
6.53% 677/2016 |
-14.61% 1123/2113 |
1.01% 1408/2208 |
| 2021 | -8.71% 1056/1822 |
-2.86% 717/1255 |
0.96% 1073/1330 |
-7.66% 1073/1466 |
0.81% 1059/1822 |
| 2020 | 32.36% 487/1250 |
-8.74% 628/1028 |
11.19% 743/1067 |
13.10% 346/1164 |
15.34% 217/1184 |
| 2019 | 44.28% 175/1092 |
25.39% 467/754 |
4.46% 28/804 |
2.28% 310/850 |
7.70% 406/918 |
| 2018 | -19.68% 174/834 |
- - |
- - |
- - |
-11.80% 350/691 |
| 2017 | 34.24% 40/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.30% 172/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 国富中证A100指数增强(LOF) VS. 长安沪深300非周期A(740101) |